Post Reply - CoViD in the 1980's ????

MAH
@Med58ll
< aria-expanded="false" aria-haspopup="menu" aria-label="More" role="" ="-175oi2r r-1777fci r-bt1l66 r-bztko3 r-lrvibr r-1loqt21 r-1ny4l3l" -testid="caret" ="" style="text-align: inherit; font-size: inherit; font-family: inherit; align-items: stretch; border-width: 0px; border-style: solid; border-color: black; display: flex; flex-basis: auto; flex-direction: column; flex-shrink: 0; list-style: none; margin: 0px; min-height: 20px; min-width: 0px; padding: 0px; : relative; : 0; overflow: ; justify-: center; cursor: pointer; outline-style: none; user-: none;">
Uit een onderzoek onder 220 ME/CVS-patiënten bleek dat 75% verbetering had na intraveneuze Remdesivir en 52% na Paxlovid, waarbij de effecten weken tot maanden aanhielden voordat er een terugval ontstond.
< aria-expanded="true" aria-label="Hide translated post" role="" ="-1jxf684 r-bcqeeo r-qvutc0 r-poiln3 r-n6v787 r-1cwl3u0 r-1loqt21 r-fdjqy7" ="" style="text-align: left; font-size: 13px; font-family: inherit; color: rgb29, 155, 240; border-width: 0px; border-style: solid; border-color: black; display: inline; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: 16px; font-optical-sizing: inherit; font-size-adjust: inherit; font-kerning: inherit; font-feature-settings: inherit; font-variation-settings: inherit; list-style: none; margin: 0px; padding: 0px; : relative; white-space: inherit; overflow-wrap: break-word; cursor: pointer; min-width: 0px;">Translated from Dutch by
A study of 220 ME/CFS patients found that 75% improved after intravenous Remdesivir and 52% after Paxlovid, with effects lasting for weeks to months before relapse.

link; https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.2514/7988721?login=false or https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.2514/7988721?login=false ;Background
Etiology remains elusive for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and no treatment exists. Antivirals had no efficacy in randomized clinical trials (RCT) for Epstein-Barr Virus and HHV-6. Enteroviruses (EV) have been implicated, but no antivirals are available. Many patients who received SARS–CoV-2-specific antiviral drugs for acute Covid-19 (COV19) infection experienced significant improvement of prior ME/CFS symptoms. This study summarizes their responses to antivirals for SARS-Cov-2.
-
Results
15/20 (75%) ME/CFS patients – 10/12 hospitalized, 5/8 non-COV19 patients – responded to IV Rem 2-6 weeks after infusions; remission lasted 6-8 weeks to 6-9 months before relapse. Of Controls: 2/20 had mild improvement (< 0.001, X 2 ).
104/200 (52%) of PAX-treated ME/CFS patients improved, often within 2-3 days; all relapsed within days to weeks after treatment. 66%, 33% and 44% of CVB4+, CVB3+, non-CVB3,4+ patients responded to treatment, respectively. EVP decreased and increased with clinical response and relapse.
Conclusion
Rem and PAX demonstrated clinical efficacy in ME/CFS patients with chronic enterovirus infections. Placebo-controlled RCT will be needed to clarify the role of antivirals in ME/CFS.

DJ, Indicating ME-CFS-like Long CoViD may be a form of chronic viral infection (with other infections sometimes on top; bacterial, fungal).